On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Inotuzumab Ozogamicin Improves Complete Remission in Poor-Prognosis ALL

Inotuzumab ozogamicin (InO), an investigational anti-CD22 antibody drug conjugate, demonstrated a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive...
On location

High Response Rates for Brentuximab Vedotin Combinations in HL and DLBLC

High response rates were the hallmark of two clinical trials of brentuximab vedotin (BV) in combination with chemotherapy presented at the 2015 American Society...
On location

Treating the High-Risk APL Patient: ATRA + ATO + GO Might Be the Key

While the combinations of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA+ATO) and of ATRA+ATO plus gemtuzumab ozogamicin (GO; ATRA+ATO+GO) have yielded good clinical...
On location

In Multiple Myeloma, Carfilzomib Bests Bortezomib, But Bortezomib Bests Observation

Two multiple myeloma (MM) studies – one in relapsed disease and the other in newly diagnosed disease after autologous stem cell transplantation (ASCT) –...
On location

PI3K Inhibitors Safe and Effective in CLL Patients

Updated data on the safety and effectiveness of three different phosphoinositide 3-kinase inhibitors (PI3K inhibitors) presented at the European Hematology Association (EHA) Congress show...
On location

Single-Agent Ibrutinib Leads to Durable Responses in CLL

In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), single-agent ibrutinib led to durable responses, according to...
On location

Pediatric Leukemia Patients May Benefit from CAR Therapy

Genetically reprogrammed T cells, which have been making waves in adult acute lymphocytic leukemia (ALL), have also shown promise in pediatric ALL patients, according...
On location

Updates on Novel Treatments for Leukemia

Three sessions at the American Association for Cancer Research Annual Meeting focused on promising, novel treatment options for patients with various forms of leukemia. In...
On location

Study Evaluates Safety of Cytotoxic T Lymphocytes for Rituximab-Refractory Epstein-Barr Virus

For patients who have undergone stem cell or organ transplantation, the drugs administered to prevent organ rejection can weaken the immune system, which can...

ASH Sickle Cell Disease Summit: A Call to Action

In mid-April, more than 60 experts in sickle cell disease (SCD), including clinicians and researchers, federal agency partners, representatives from industry, and other members...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.